Roivant Sciences Ltd (NASDAQ: ROIV) kicked off on Tuesday, up 3.86% from the previous trading day, before settling in for the closing price of $11.93. Over the past 52 weeks, ROIV has traded in a range of $8.73-$13.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -99.51% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -413.74%. With a float of $429.99 million, this company’s outstanding shares have now reached $682.23 million.
In an organization with 750 employees, it is important to assess its efficiency.
Roivant Sciences Ltd (ROIV) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Roivant Sciences Ltd is 37.03%, while institutional ownership is 64.13%. The most recent insider transaction that took place on Aug 20 ’25, was worth 1,172,000. In this transaction President & Immunovant CEO of this company sold 100,000 shares at a rate of $11.72, taking the stock ownership to the 1,653,585 shares. Before that another transaction happened on Aug 20 ’25, when Company’s Officer proposed sale 100,000 for $11.72, making the entire transaction worth $1,172,120.
Roivant Sciences Ltd (ROIV) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.3 earnings per share (EPS), lower than consensus estimate (set at -0.24) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -413.74% per share during the next fiscal year.
Roivant Sciences Ltd (NASDAQ: ROIV) Trading Performance Indicators
Take a look at Roivant Sciences Ltd’s (ROIV) current performance indicators. Last quarter, stock had a quick ratio of 40.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 364.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.70, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.37 in one year’s time.
Technical Analysis of Roivant Sciences Ltd (ROIV)
Let’s dig in a bit further. During the last 5-days, its volume was 5.53 million. That was inferior than the volume of 5.75 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 71.26%.
During the past 100 days, Roivant Sciences Ltd’s (ROIV) raw stochastic average was set at 97.89%, which indicates a significant increase from 91.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.28 in the past 14 days, which was lower than the 0.32 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.52, while its 200-day Moving Average is $11.17. However, in the short run, Roivant Sciences Ltd’s stock first resistance to watch stands at $12.59. Second resistance stands at $12.79. The third major resistance level sits at $13.12. If the price goes on to break the first support level at $12.06, it is likely to go to the next support level at $11.74. Assuming the price breaks the second support level, the third support level stands at $11.54.
Roivant Sciences Ltd (NASDAQ: ROIV) Key Stats
The company with the Market Capitalisation of 8.46 billion has total of 682,882K Shares Outstanding. Its annual sales at the moment are 29,050 K in contrast with the sum of -171,980 K annual income. Company’s last quarter sales were recorded 2,170 K and last quarter income was -223,360 K.
